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ABSTRACT 
Niosomes or non- ionic surfactants vesicles are one of the many different carriers for transporting a drug molecule to its site of action. 
Niosomes are vesicular system similar to liposomes that can be used for amphiphilic and lipophilic drugs. Niosomes are biocompatible, 
biodegradable, non- immunogenic and exhibit flexibility. Niosomes has been widely used for controlled release drug delivery system. Niosomes 
can entrap both hydrophobic and hydrophilic drugs.  Niosomes are chemically stable drug delivery systems. Niosomes are biocompatible, 
biodegradable, non- immunogenic and exhibit flexibility in structure. Niosomes have been widely used for controlled drug delivery system. 
They have been prepared with different ratios of surfactants and cholesterol and their properties have been determined by scanning electron 
microscopy. There are five batches of Levamisole niosomal preparations were prepared by changing the surfactant concentration  but keeping 
the cholesterol concentration constant. The surfactant used Span40 and the five batches of niosomal preparations in the ratios of 1:1:1, 1:2:1, 
1:3:1, 1:4:1 and 1:5:1 (Surfactant: cholesterol: drug). Furthermore, the release profiles, entrapment efficiency, size distribution and stability of 
these niosomes under various temperatures were studied. Niosomes were prepared using Span40 by using sonication method. The test changes 
in the characteristics of the liposomes.  
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INTRODUCTION 
Novel Drug Delivery System: Novel drug delivery system is 
based on physical mechanisms and biological mechanisms. 
Physical mechanisms referred as controlled drug delivery 
system includes osmosis, dissolution, erosion and electro- 
transport. Biochemical mechanisms include monoclonal 
antibodies, drug addicts and liposomes. New drug delivery 
system consists of duration of action of drug, increasing dose 
frequency. Drug carrier’s soluble polymers are made up of 
biodegradable natural and synthetic polymers. These 
carriers can slowly stimuli (example- PH Sensitive) and 
targeted (conjugate specific antibodies). These two 
mechanisms can be represented as- a) passive b) Drug 
targeting. Novel drug delivery system may be divided into 2 
classes- 
a) Sustained release drug delivery system 
b) Controlled release drug delivery system 
Drug Delivery Carriers 
Drug carrier systems such as crystal dispersions as well as 
10-400nm diameter. They are developed by formulations 
used to system with optimized properties. 
Drug Targeting 
Drug targeting may be defined as the ability to directly a 
therapeutic agent specifically to desired a site of action with 
non- target tissue. The vesicles forming amphiphile is a non- 
ionic surfactants such as Span40 which is usually stabilized 
by addition of cholesterol. The first report of non- ionic 
surfactant vesicles come from the cosmetics applications 
described by Loreal. Various types of drug deliveries can be 
possible using niosomes like targeting, ophthalmic, topical, 
parentral etc. 
Levamisole is a veterinary drug used to treat parasitic 
infestations in animals. It is available in a white crystalline 
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powder, and in pastes gels, tablets, feed premixes and topical 
and injectable solutions.  
A dose of 2.5mg/kg has been recommended for 
antihelminthic therapy in humans and a dose of 50mg. 3 
times a day, for 3 day every other week for colon cancer 
therapy in Levamisole approved countries. 
2) MATERIALS AND METHODS 
2.1) Materials- 
Cholesterol, sorbitan monopalmitate (Span40), chloroform, 
Methanol, n- propanol were procured from central drug 
house Lab Reagents, Delhi, India and drug Levamisole was 
obtained as a gift sample for Life Sciences Pvt. Ltd., 
Gurugram, India. 
3) Pre- formulation studies- 
Preformulation study is the process of optimizing the drug 
delivery through determination of various physicochemical 
properties of active compound. It is an investigation to 
determine the physicochemical properties of active 
compound which could affect the drug performance and 
development. It is an investigation to determine the physical 
and chemical properties of drug substance alone and with 
excipients to ensure its good quality. Preformulation studies 
consist of melting point determination, solubility and 
partition coefficient. The drug- excipient compatibility was 
carried using FT-IR Spectroscopy3, 4. 
Determination of λ MAX 
The absorption maxima of Levamisole hydrochloride were 
scanned between 200- 400 nm. λ max of the drug was 
determined by UV- Visible spectrophotometric method to 
obtain the structural information regarding of Levamisole 
Hydrochloride. 
Fourier Transform Infra- Red (FTIR) Spectroscopy- 
IR study was performed for identification and structural 
analysis of procured drug and polymer by using Perkin 
Fourier Transform Infrared Spectroscopy. The absorption 
maxima spectrum was compared with the reference 
spectrum. 
Scanning Electron Microscopy (SEM)- 
The sizes of the vesicles were measured by scanning electron 
microscopy (HITACHI-150). A small amount of sample of 
niosomes was taken in a cover slip on the specimen stub. It 
was coated with carbon and then gold vapour using HITACHI 
vaccum evaporator, model HITACHI S GB. 
Preparation of Standard Curve of Levamisole- 
100 mg of Levamisole was accurately weighed and dissolved 
in a small quantity of methanol and made up to 100ml with 
methanol. From this primary solution, 10ml was pipetted out 
and made up to 100ml with water. From this secondary 
solution aliquots were taken to produce concentration of 
2,4,6,8 and 10ug/ml. The absorbance of the resulting 
solution was measured at 215nm in the UV- Visible 
Spectrophotometer (Shimadzu).  
Preparation of Niosomes by Sonication Method11. 
The niosomes were prepared by sonication method. 
Accurately weighed quantities of drug (200mg), non- ionic 
surfacatnts Span40 (200mg) and cholesterol were dissolved 
in quantity (10ml) of solvent mixture, chloroform (50ml): 
Methanol (25ml) 2:1 to give a clear solution. The resulting 
solution is poured into a sonicator. The sonicator was 
removed from the bath and allowed to return at room 
temperature. The film formed was hydrated with 20ml of 
distilled water while sonicator at gentle agitation at a 
temperature. The resulting niosomes suspension was stored 
in tightly closed container in a refrigerator. 
 
Formulation Code Non-Ionic Surfacatnts Drug: Surfactant: Cholesterol (m moles) 
LVS40-1 SPAN 40 1:1:1 
LVS40-2 SPAN 40 1:2:1 
LVS40-3 SPAN 40 1:3:1 
LVS40-4 SPAN 40 1:4:1 
LVS40-5 SPAN 40 1:5:1 
 
Characterization of Drug Loaded Span40 Niosomes- 
Determination of drug content-The amount of drug (100mg) 
in the formulation was determined by lysing the niosomes 
using 5% of N- Propanol 1ml of the niosomes preparation 
was pipetted out, sufficient quantity of 50% N- Propanol was 
added and shaken well for the complete lysis of the vesicles. 
After suitable dilution with water containing 10% methanol, 
the absorbance of the solution was measured at 215nm in 
the UV- Visible Spectrophotometer. The excess mixture 
without the drug treated in the similar manner as the 
niosome suspension was used as blank. The drug content 
was calculated.  
Determination of Entrapment Efficiency- Niosomes 
containing Levamisole was separated from unentrapped 
drug by centrifugation. The Entrapment Efficiency of the 
formulation was determined by centrifuging 1ml of the 
suspension diluted to 10ml with distilled water at 15,000 
rpm for 60 minutes at 40 C using a high speed cooling in 
order to separate niosomes from unentrapped drug. The free 
drug concentration at 215nm using UV- Visible 
spectrophotometer after suitable dilution. The percentage of 
drug entrapment in niosomes was calculated by using the 
following formula- 
% Drug Entrapment = (Total drug- Drug in supernatant 
liquid)/ Total drug X 100 
 Drug Dissolution Studies- 
Kinetics modelling of in- vitro drug release  
1) Zero- order kinetics model-  
Drug release study can be expressed by the equation-  
Qo – Qt = Kot……………………………. (1) 
Rearrangement of equation I  
Qt = Qo + Kot…………………………… (2) 
Where, Qt is the amount of drug dissolved in time t. Qo is the 
initial amount of drug in the solution and KO is the zero 
order release.  
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Data obtained from in- vitro drug release were plotted as 
cumulative amount of drug release versus time. 
2) First – order kinetics model 
This model has been described by the absorption of some 
drugs. The release of the drug which followed first order 
kinetics can be expressed as: 
Dc/ DT = - Kt ……………………………. (3) 
Where, X is the first order rate constant, and t is the time.  
The data obtained as plotted as log cumulative %age of drug 
remaining versus time which would yields a straight line 
with a slope of –k/2.303. 
3) Higuchi Model Kinetics Model- 
This model is based on hypothesis that- 
1) Initial drug concentration in matrix is much higher 
than drug solubility. 
2) Drug diffusion takes place. 
3) Drug diffusion are much smaller than system.  
4) Perfect sink conditions are always attained in the 
release environment. 
   F1= Q  √    (     )    
    --------------------------- (5) 
Where, Qis the amount of drug released in time t per unit 
area A, C is the drug solubility in the matrix media and D is 
the diffusivity of the drug molecules (diffusion coefficient) in 
the matrix substance. 
The relation is valid during all the time, except when the 
total depletion of the drug in the therapeutic a planar 
heterogenous matrix system, where the drug concentration 
in the matrix is lower than its solubility and the release 
occurs through pores in the matrix, the expression is given 
equation- 
Ƒ1=Q=
√   
 
 (      )    ----------------------------------- (6) 
Where D is the diffusion coefficient of the drug molecule in 
the solvent, S is the porosity of the matrix, T is the tortuosity 
of the matrix and Q, A, C and t have the meaning assigned 
above. Tortuisity is defined as the dimensions of radius and 
branching of the pores and canals in the matrix. In a general 
way it is possible to simplify the Higuchi model as generally 
known as the simplified Higuchi model: 
Ƒ1 = Q = KH X t1/2------------------------------------------------ (7) 
Where, KH is the Higuchi dissolution constant. 
The data obtained were plotted as cumulative percentage 
drug release versus square root of time.  
D) KORSMEYER- PEPPAS MODEL KINETICS- 
 To find out the mechanism of drug release, first 60% drug 
release data were fitted in Korsmeyer- peppas model. 
 Mt/ M∞ = Ktn--------------------------------------------------- (8) 
Where, Mt/M∞ is a fraction of drug released at a time t, k is 
the release rate constant and n is the release exponent. The n 
value is used to characterize different release for cylindrical 
shaped matrices. 
In this model, the value of n characterize the release 
mechanism of drug. For the case of cylindrical, 0.45<n< 0.89 
to non- Fickian transport, and n= o.89 to case 2 transport. To 
find out the exponent of n the portion of the release curve, 
where Mt/ M∞ < 0.6 should only be used. To study the 
release kinetics, data obtained from in- vitro drug release 
studies were plotted as log cumulative %age drug release 
versus log time.  
Stability Studies- 
 The niosomal dispersions were kept in the air tight 
containers and stored at 2-8.C and at room temperature 
(30±2.C) for 30 days and 2ml samples were withdrawn 
every 15 days and at the end of 45 days. The samples were 
analysed spectrophotometrically at Ϡ max 210nm after 
disrupting the vesicles with 50% n- propanol. 
Optimization of Process- Related Variables- 
a) Effect of hydration time102, 103 
 The niosomal formulations containing Span40 at different 
ratios and a fixed amount of cholesterol (1:1:1, 1:2:1, 1:3:1) 
were hydrated with 10ml of distilled water for 30minutes. 
The vesicle formations and entrapment efficiency of the 
formulations were calculated by centrifugation method. 
b) Effect of sonication method- 
The niosomal formulations containing Span40 at different 
ratios and a fixed amount of cholesterol (1:1:1, 1:2:1, 1:3:1, 
1:4:1, 1:5:1) were subjected to ultrasonic vibration using 
ultra sonicator. To study the effect of sonication time, the 
formulations were subjected to sonicator for various time 
intervals (1min, 2min, 3min, 4min, and 5min). The 
entrapment efficiency of the formulations were measured. 
RESULTS AND DISCUSSION 
FT-IR Spectrophotometry-. The FT-IR spectra of the drug 
and the formulations LVS40- 5 are shown in following 
figures, tables.  
 
 
Figure 1: FT-IR Spectra of Levamisole 
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Scanning Electron Microscopy (SEM) 
 
Figure 2: SEM Photograph 
Preparation of Standard Curve of Levamisole- 
The UV- Spectrophotometer was used to analyser 
Levamisole. The absorbance of the drug in water with small 
amount of methanol was measured at a wavelength of 
215nm 
Table 1: Data for calibration curve of Levamisole 
S.N. Concentration(µg/Ml) Absorbance 
1     1ml     0.011 
2     2ml     0.021 
3      3ml     0.031 
4       4ml     0.041 
5        5ml     0.051 
 
 
Optimization of Process Related Variables- 
A) Effect of Hydration time- 
The niosomes formulations were hydrated with 20ml 
distilled water for 40, 45, 70 and 90 minutes. The parameters 
like vesicle formulation and entrapment efficiency was 
studied. The results indicated that vesicles were not formed 
properly but resulted in aggregates with hydration time of 
30 minutes. On increase in hydration time, the spherical 
vesicles were formed and the entrapment efficiency also 
increased with increase in hydration time from 30 minutes 
to 60 minutes. 
Table 2: Effect of Hydration time on entrapment 
efficiency 
S.N.  Hydration Time  Entrapment Efficiency 
(%w/w) 
1)    30  32.06± 1.52 
2)    45  40.5 ± 1.16 
3)    60  76.2 ± 0.13 
4)    75  72.52 ± 1.7 
5)    90 70.27 ± 1.15 
 
*Mean SD (n=3) 
B) Effect of sonication time – 
Formulations were sonicated 3 times for 5 minutes with 2 
sec running time and 1 second interval spherical vesicles 
were not observed after 10 minutes of sonication resulted 
uniform uni-lamellar vesicles. 
Table 3: Effect of sonication time on Entrapment 
efficiency 
S.N,  Sonication Time      
( minutes) 
Entrapment Efficiency 
(%w/w) 
1)       0   42.06 ± 0.122 
2)       0.5   52.12 ± 0.010 
3)      10   61.16 ± 0.042 
4)      15   52.21 ± 0.089 
5)      20  55.23 ± 1.13 
 
 
Characterization of Drug Loaded Span40 Niosomes  
a) Determination of drug content and Entrapment Efficiency-  
Table 4: Drug content and Entrapment Efficiency of Levamisole niosomes containing span-40 
FORMULATION CODE  DRUG CONTENT (%W/W) %ENTRAPMENT EFFICIENCY (%W/W) 
LVS40-1 55.63    63.2 
LVS40-2  56.98    64.7 
LVS40-3  57.32  65.22 
LVS40- 4 58.22 66.54 
LVS40- 5 61.34 68.32 
                                   
The drug content was found to be 55.63%, 56.98%, 57.32%, 
58.22%, and 61.34% for the formulations LVS40-1. The 
entrapment efficiency was found to be 63.2%, 64.7%, 
65.22%, 66.54%, and 68.32% for the formulations LVS40-1. 
The highest entrapment efficiency was observed with Span 
40 formulations niosomes in the similar range. This may be 
due to the higher HLB value of span 40 as compared to 
Span60. The entrapment efficiency as the HLB Value 
decreased from 6.7 of Span40.  This may be due to the 
difference in phase transition temperature. The order of non- 
ionic surfactants that resulted in better entrapment 
efficiency is as follows:- 
                SPAN40 > SPAN60
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Figure 3: Drug content of LVS 40 
Drug Dissolution Studies  
Kinetic modelling of drug 
1) Zero- order kinetic model-  
 
Figure 4: zero order kinetic data for levamisole niosomes 
 
2) First order model kinetic- 
 
Figure 5: First order kinetics data for levamisole Niosomes 
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3) Higuchi Model kinetic- 
 
Figure 6: Higuchi model kinetic data for Levamisole niosomes 
 
4) Korsmeyer- Peppas model kinetics 
 
Figure 7: Korsmeyer peppas model kinetic data for levamisole niosomes 
 
Kinetic Modelling of Levamisole Niosomes- 
Table 5: Kinetic modelling of niosomes formulations 
Formulations  Zero order  
Kinetic data 
(r2) 
First order 
Kinetic data 
(r2) 
Higuchi 
model  
Kinetic data 
(r2) 
Peppas model  
Kinetic data 
(r2) 
Peppas model 
Kinetic  
Data (n value) 
 
Best fit 
model  
F1 0.9608 0.9889 0.9558 0.8815 1.2565 Zero order 
F2 0.9603 0.9778 0.9559 0.5886 1.3345 Zero order 
F3 0.9514 0.9848 0.9514 0.5622 1.2687 Zero order 
F4 0.9542 0.9942 0.9655 0.6703 1.3552 Zero order  
F5 0.9426 0.9881 0.9433 0.6384 1.2262 Zero order  
 
y = 22.356x - 5.1256 
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CONCLUSION- 
This research affirmed the sustained release of Levamisole 
hydrochloride loaded span40 niosomes can be attained by 
Sonication method using Span40 as polymer. DSC and FTIR 
studies exposed that there is no interaction between the 
drug and polymer which implies that the drug and polymer. 
The five batches were evaluated for drug content, drug 
loading and entrapment efficiency. The batch 3 (CLP-3) with 
the drug and polymer ratio 1:3:1 was considered to be 
superior which showed maximum drug content and 
entrapment efficiency and prolonged release of drug. The 
drug release from niosomes was affected by various Span40 
concentrations. Scanning electron microscopy (SEM) studies 
revealed that the niosomes were spherical. The drug release 
was found to be in sustained manner from batch 3 (LVS-3). 
Therefore, it was concluded the Levamisole hydrochloride 
loaded Span40 niosomes were found to be best in treatment 
of worm skin infections with reduced the side effect on skin 
and better diagnosis a sustained release manner.
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